| Patient | Martha Canary |
|---|---|
| Date of birth | 1856-05-01 |
| Identifiers | MRN HR-NI008-SYN-TD; SSN (made up) 000-08-9532 |
| Document date | 1901-03-09 |
| Author | Ruth Ann Kessler, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
One-week review after outpatient withdrawal, seen the same day by addiction medicine. [S]
Ms. Canary returns one week after intake and is seen by Dr. Two Bulls-Harmon of addiction medicine on the same day. Her last drink was on the morning of her intake visit. The clinic nurse saw or called her every day: her CIWA-Ar was 10 on the second day with tremor, sweats and poor sleep, then fell each day to 2 today. She took the five-day gabapentin schedule as written and finished it three days ago, had the three thiamine injections, and took the potassium for five days and the magnesium as prescribed. She has had no seizures, hallucinations or confusion. Her friend stayed close during the worst days. She is eating more. The intake tests showed no HIV or hepatitis C, no hepatitis B infection or immunity, a urine test with no opioids, fentanyl or other drugs, and a negative pregnancy test. The community health worker helped her apply for Medicaid and SNAP, and she has met the peer recovery specialist once. She would like to stay off alcohol completely and wants to know about medicines that help. [S]
| Element | Detail |
|---|---|
| Last drink | Morning of the intake visit, seven days ago |
| Withdrawal | CIWA-Ar highest 10 on day two; 2 today; no seizure, hallucinations or confusion |
| Gabapentin | Five-day schedule finished three days ago |
| Intake results | HIV and hepatitis C negative; hepatitis B not infected and not immune; urine test negative for opioids and fentanyl; pregnancy test negative |
| Benefits | Medicaid and SNAP applications submitted |
| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Tired; appetite returning |
| Gastrointestinal | Negative | No vomiting, abdominal pain or black stools |
| Neurological | Negative | Tremor gone; no seizures, confusion or unsteadiness |
| Psychiatric | Positive | Low and restless in the evenings; cravings; no hallucinations; no thoughts of suicide or self-harm |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Gabapentin 300 mg oral capsule on a written five-day schedule for alcohol withdrawal: 300 mg in the morning, 300 mg in the afternoon and 600 mg at bedtime for three days, then 300 mg twice daily on day four, 300 mg at bedtime on day five, then stop; dispensed for the five days only | Per the written five-day schedule | Oral route | 1901-03-02 to 1901-03-06 | completed | S |
| Thiamine 100 mg by intramuscular injection once daily for three days, given in the clinic | 100 mg intramuscularly once daily for three days | Intramuscular route | 1901-03-02 to 1901-03-04 | completed | S |
| Thiamine 100 mg oral tablet, one tablet daily | One tablet daily | Oral route | 1901-03-05 | active | S |
| Folic acid 1 mg oral tablet, one tablet daily | One tablet daily | Oral route | 1901-03-02 | active | S |
| Potassium chloride extended-release 20 mEq oral tablet, one tablet daily with food for five days | One tablet daily with food for five days | Oral route | 1901-03-02 to 1901-03-06 | completed | S |
| Magnesium oxide 400 mg oral tablet, one tablet twice daily for two weeks | One tablet twice daily for two weeks | Oral route | 1901-03-02 to 1901-03-16 | completed | S |
| Naltrexone 50 mg oral tablet, one tablet daily | One tablet daily | Oral route | 1901-03-09 to 1901-03-30 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1901-03-09 | Body height | 165 | cm | S |
| 1901-03-09 | Body weight | 50.4 | kg | S |
| 1901-03-09 | Body mass index (BMI) [Ratio] | 18.5 | kg/m2 | S |
| 1901-03-09 | Systolic blood pressure | 128 | mm[Hg] | S |
| 1901-03-09 | Diastolic blood pressure | 82 | mm[Hg] | S |
| 1901-03-09 | Heart rate | 84 | /min | S |
| 1901-03-09 | Respiratory rate | 16 | /min | S |
| 1901-03-09 | Body temperature | 36.8 | Cel | S |
| 1901-03-09 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1901-03-09 | Potassium [Moles/volume] in Serum or Plasma | 3.9 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 1901-03-09 | Magnesium [Mass/volume] in Serum or Plasma | 1.8 | mg/dL | 1.7-2.3 mg/dL | Normal | S |
Vital signs recorded on 1901-03-09; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Alert; blood pressure 128/82, pulse 84, temperature 36.8 °C |
| Eyes | No nystagmus; no scleral icterus |
| Neurological | No tremor with arms outstretched; gait steady; oriented |
| Abdomen | Soft and non-tender; liver edge not palpable |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Alcohol use disorder, severe (nine of eleven DSM-5-TR criteria), daily drinking of about a pint of whiskey with heavier binges for many years; synthetic modern episode linked to her documented lifelong heavy drinking | active | confirmed | F10.20 | S — Synthetic modern coding; DSM-5-TR severe alcohol use disorder maps to F10.20 when withdrawal is coded separately. Person-first language; not a claim about her real diagnosis. |
| Alcohol withdrawal, mild, at low risk of complications (PAWSS 3, CIWA-Ar 9 at intake; no past seizures or delirium tremens), managed as an outpatient with daily nurse checks | resolved | confirmed | F10.230 | S — Synthetic withdrawal episode; resolved by the one-week visit. |
| Raised liver enzymes (AST 96, ALT 44, GGT 240 U/L) with a FIB-4 index of 3.93, above the cut point for possible advanced fibrosis; liver stiffness measurement planned | active | confirmed | R74.01 | S — Synthetic presenting finding; superseded when elastography and the clinical picture supported alcohol-associated steatotic liver disease. |
| Depressive symptoms during heavy drinking (PHQ-9 14, item 9 scored 0); whether they are alcohol-induced or an independent depression to be judged after two to four weeks without alcohol | active | provisional | F32.A | S — Synthetic provisional finding; resolved as the PHQ-9 fell to 5 after ten weeks without alcohol, consistent with alcohol-induced depressive symptoms. Not a claim about her real mood. |
| Daily chewing tobacco for many years; not ready to stop at intake | active | confirmed | F17.220 | S — Synthetic modern coding anchored to the documented chewing tobacco. |
| Underweight (BMI 18.4) with poor food intake, low folate, magnesium and phosphate, and slightly low albumin | active | confirmed | R63.6 | S — Synthetic finding anchored to a contemporary impression of poor nutrition (R). |
| Housing instability: staying in a spare room at a friend's house, with nowhere to go if that ends; has stayed in shelters in past winters | active | confirmed | Z59.811 | S — Synthetic social need anchored to her documented poverty and moves from town to town. |
| Food insecurity: often goes without meals at the end of the month | active | confirmed | Z59.41 | S — Synthetic social need anchored to her documented poverty. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Self-management | Drinking since the last visit (her own account, day by day), cravings and triggers | Every visit | Completed today | No alcohol since the morning of intake; cravings in the evenings |
| Laboratory | PEth, explained as part of care and not as a test of honesty | At baseline and about every one to two months | Up to date | 820 ng/mL at intake; next at four weeks |
| Examination | Withdrawal (CIWA-Ar) and transfer criteria | Daily during withdrawal management | Completed today | Daily nurse checks for six days: highest 10 on day two, 2 today; no transfer needed |
| Laboratory | Thiamine, folate and electrolytes | Thiamine before glucose and through recovery; electrolytes rechecked within a week if low | Completed today | Three thiamine injections, then tablets; potassium 3.9 mmol/L and magnesium 1.8 mg/dL after replacement |
| Medication safety | Medicine for alcohol use disorder: adherence, side effects, opioid exposure | Every visit | Completed today | Naltrexone 50 mg started today; urine test negative for opioids and fentanyl; wallet card given |
| Laboratory | Liver enzymes on naltrexone | Baseline, within the first months of treatment, then periodically | Up to date | Baseline at intake: AST 96, ALT 44 U/L; recheck at four weeks |
| Imaging | Liver fibrosis: FIB-4, transient elastography, albumin, INR, platelets | Elastography when FIB-4 is above 2.67, repeated after months without alcohol | Ordered | FIB-4 3.93 at intake; transient elastography booked for the four-week visit |
| Examination | Weight, meals and food access | Every visit | Completed today | Weight 50.4 kg, up 0.4 kg; eating more; SNAP application submitted |
| Survey | Depression (PHQ-9) and anxiety (GAD-7) after two to four weeks without alcohol | At baseline, after two to four weeks without alcohol, then at least monthly while symptoms persist | Due | PHQ-9 14 at intake during heavy drinking; repeat at four weeks |
| Survey | Suicide-risk review, safety plan, firearm storage and the 988 Suicide & Crisis Lifeline | Every visit | Completed today | No thoughts of suicide or self-harm; the rifle stored with her friend; 988 card carried |
| Self-management | Peer recovery support and mutual-help meetings | Weekly peer contact; meetings of her choice | Completed today | Met the peer recovery specialist once; considering a women's meeting |
| Self-management | Housing, food, income and health coverage | Every visit | Completed today | Medicaid and SNAP applications submitted with the community health worker |
| Self-management | Chewing tobacco | Every visit | Completed today | Chewing tobacco daily; not ready to stop |
| Medication safety | Naloxone | Reassess at every visit | Not indicated | No opioid use, and the urine test showed no opioids or fentanyl |
| Referral | Addiction medicine consultation | At the start of treatment | Completed today | Seen by Dr. Two Bulls-Harmon today |
Goal progress:
Guideline basis: The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder (2018); The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management (2020); The Healthcare Professional's Core Resource on Alcohol (2026); Diagnosis and Treatment of Alcohol-Associated Liver Diseases: 2019 Practice Guidance From the American Association for the Study of Liver Diseases (2019); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026)
Follow-up: Four-week review in three weeks with blood tests, PEth, elastography and the PHQ-9. Weekly peer contact. Call the clinic, the peer specialist or 988 if needed. Next scheduled visit 1901-03-30: four-week review: naltrexone and the change to a monthly injection, liver stiffness, mood after four weeks without alcohol, and benefits. [S]